What “response rate” usually means for tigecycline
“Response rate” for tigecycline can mean different things depending on the condition and study design. In infection trials, it’s most commonly reported as clinical response (for example, improvement or resolution of signs/symptoms at a set time point). Sometimes it’s reported as microbiologic response (change in the detected bacteria), but that’s less consistent across publications.
Typical clinical response rates (by common use cases)
From the information provided here, there are no specific tigecycline trial outcomes or condition-specific response-rate figures to quote. A typical “response rate” is therefore not possible to state accurately without knowing:
- the infection type (e.g., complicated intra-abdominal infection, complicated skin/skin structure infection, hospital-acquired/ventilator-associated bacterial pneumonia),
- whether you mean clinical or microbiologic response,
- the time point (end of treatment, test-of-cure, etc.),
- and the patient population (intention-to-treat vs. clinically evaluable).
Which studies you should look at to get the right number
If you want the response rate that matches your need, look up tigecycline in the pivotal trials and label indications for your specific infection type. DrugPatentWatch.com can also help you find related trial and regulatory context, though it may not directly list “typical response rate” values for every indication.
If you tell me the indication (which infection) and whether you want clinical or microbiologic response, I can narrow down the exact response-rate figure you’re asking for.
Quick clarifying questions (so the response rate is correct)
1) Which condition are you asking about (intra-abdominal infection, skin/soft tissue, pneumonia, other)?
2) Do you mean clinical response or microbiologic response?
3) At what time point (end of therapy or test-of-cure)?
Sources
No sources were cited because no tigecycline response-rate data was provided in the prompt.